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REGULAR ARTICLE
Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic
cell transplantation for chronic myeloid leukemia
Saurabh Chhabra,1 Kwang Woo Ahn,2,3 Zhen-Huan Hu,3 Sandeep Jain,4 Amer Assal,5 Jan Cerny,6 Edward A. Copelan,7 Andrew Daly,8
Zachariah DeFilipp,9 Shahinaz M. Gadalla,10 Robert Peter Gale,11 Siddhartha Ganguly,12 Betty K. Hamilton,13 Gerhard Carl Hildebrandt,14
Jack W. Hsu,15 Yoshihiro Inamoto,16 Abraham S. Kanate,17 H. Jean Khoury,18 Hillard M. Lazarus,19 Mark R. Litzow,20 Sunita Nathan,21
Richard F. Olsson,22,23 Attaphol Pawarode,24 Olle Ringden,22 Jacob M. Rowe,25 Ayman Saad,26 Bipin N. Savani,27 Harry C. Schouten,28
Sachiko Seo,29 Nirav N. Shah,1 Melhem Solh,30 Robert K. Stuart,4 Celalettin Ustun,31 Ann E. Woolfrey,32 Jean A. Yared,33 Edwin P. Alyea,34
Matt E. Kalaycio,13 Uday Popat,35 Ronald M. Sobecks,13 and Wael Saber3
1Division of Hematology/Oncology, Department of Medicine, 2Division of Biostatistics, Institute for Health and Society, and 3Center for International Blood and Marrow
Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI; 4Division of Hematology/Oncology, Department of Medicine, Medical University
of South Carolina, Charleston, SC; 5Columbia University Medical Center, New York, NY; 6UMass Memorial Medical Center, Worcester, MA; 7Department of Hematologic
Oncology and Blood Disorders, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; 8Tom Baker Cancer Centre, Calgary, AB, Canada; 9Blood and Marrow
Transplant Program, Massachusetts General Hospital, Boston, MA; 10Division of Cancer Epidemiology & Genetics, National Cancer Institute Clinical Genetics Branch,
National Institutes of Health, Rockville, MD; 11Hematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London,
United Kingdom; 12Blood and Marrow Transplantation, Division of Hematology and Oncology, University of Kansas Medical Center, Kansas City, KS; 13Department of
Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH; 14Markey Cancer Center, University of Kentucky, Lexington, KY; 15Division of Hematology &
Oncology, Department of Medicine, Shands HealthCare & University of Florida, Gainesville, FL; 16Division of Hematopoietic Stem Cell Transplantation, National Cancer
Centers Hospital, Tokyo, Japan; 17Osborn Hematopoietic Malignancy and Transplantation Program, West Virginia University, Morgantown, WV; 18Emory University Hospital,
Atlanta, GA; 19Seidman Cancer Center, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH; 20Division of Hematology and
Transplant Center, Mayo Clinic Rochester, Rochester, MN; 21Rush University Medical Center, Chicago, IL; 22Division of Therapeutic Immunology, Department of Laboratory
Medicine, Karolinska Institutet, Stockholm, Sweden; 23Centre for Clinical Research Sormland, Uppsala University, Uppsala, Sweden; 24Blood and Marrow Transplantation
Program, Division of Hematology/Oncology, Department of Internal Medicine, The University of Michigan Medical School, Ann Arbor, MI; 25Department of Hematology, Shaare
Zedek Medical Center, Jerusalem, Israel; 26Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL; 27Division of
Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN; 28Department of Hematology, Academische Ziekenhuis, Maastricht, The
Netherlands; 29Department of Hematology & Oncology, National Cancer Research Center East, Chiba, Japan; 30The Blood and Marrow Transplant Group of Georgia, Northside
Hospital, Atlanta, GA; 31Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota Medical Center, Minneapolis, MN; 32Fred
Hutchinson Cancer Research Center, Seattle, WA; 33Blood & Marrow Transplantation Program, Division of Hematology/Oncology, Department of Medicine, Greenebaum Cancer
Center, University of Maryland, Baltimore, MD; 34Center of Hematologic Oncology, Dana-Farber Cancer Institute, Boston, MA; and 35MD Anderson Cancer Center, Houston, TX
Key Points
• RIC is a reasonable alter-
native to MAC for CML
patients in the TKI era.
• In CML patients, RIC
results in similar survival
as MAC, albeit at the
expense of increased
early posttransplant
relapse.
Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative
treatment of chronicmyeloid leukemia (CML). Optimal conditioning intensity for allo-HCT
for CML in the era of tyrosine kinase inhibitors (TKIs) is unknown. Using the Center for
International Blood and Marrow Transplant Research database, we sought to determine
whether reduced-intensity/nonmyeloablative conditioning (RIC) allo-HCT and
myeloablative conditioning (MAC) result in similar outcomes in CML patients. We
evaluated 1395 CML allo-HCT recipients between the ages of 18 and 60 years. The disease
status at transplant was divided into the following categories: chronic phase 1, chronic
phase 2 or greater, and accelerated phase. Patients in blast phase at transplant and
alternative donor transplants were excluded. The primary outcome was overall survival
(OS) after allo-HCT. MAC (n 5 1204) and RIC allo-HCT recipients (n 5 191) from 2007 to
2014 were included. Patient, disease, and transplantation characteristics were similar,
with a few exceptions. Multivariable analysis showed no significant difference in OS
between MAC and RIC groups. In addition, leukemia-free survival and nonrelapse
mortality did not differ significantly between the 2 groups. Compared with MAC, the RIC
Submitted 16 August 2018; accepted 4 October 2018. DOI 10.1182/
bloodadvances.2018024844.
Presented orally at the 59th annual meeting of the American Society of Hematology,
Atlanta, GA, 11 December 2017.
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group had a higher risk of early relapse after allo-HCT (hazard ratio [HR], 1.85; P 5 .001).
The cumulative incidence of chronic graft-versus-host disease (cGVHD) was lower with
RIC than with MAC (HR, 0.77; P 5 .02). RIC provides similar survival and lower cGVHD
compared with MAC and therefore may be a reasonable alternative to MAC for CML
patients in the TKI era.
Introduction
With the remarkable success of tyrosine kinase inhibitors (TKIs) for
the treatment of patients with chronic myeloid leukemia (CML), the
use of allogeneic hematopoietic cell transplantation (allo-HCT) since
the turn of the century has dramatically decreased.1-4 Nonetheless,
allo-HCT is a useful and potentially curative treatment option for a
subset of CML patients who are refractory to or intolerant of TKIs and
those who present in accelerated phase (AP) or blast phase (BP).5-8
Traditionally, myeloablative conditioning (MAC) is the standard
intensity for CML patients in need of allo-HCT.8-10 MAC is, however,
characterized by a high risk of toxicity and nonrelapse mortality
(NRM), especially among patients with comorbid conditions and
advanced age. This prompted exploration of reduced-intensity/
nonmyeloablative conditioning (RIC) regimens.11,12
Retrospective studies comparing MAC with RIC in patients with
acute myeloid leukemia (AML) or myelodysplastic syndromes sug-
gested that RIC was associated with increased relapse but reduced
NRM, resulting in similar overall survival (OS), even though patients
receiving RIC were older and/or less fit.13-21 In contrast, a randomized
phase 3 study (BMT CTN protocol 0901) demonstrated that in fit
(hematopoietic cell transplant-comorbidity index [HCT-CI] #4)
patients with AML or myelodysplastic syndromes in remission
between the ages of 18 and 65 years receiving allo-HCT from
HLA-identical sibling or unrelated donors, RIC resulted in lower
NRM but a significant disadvantage in leukemia-free survival (LFS)
compared with MAC.13 It is remarkable that in the era of TKIs,
there is a dearth of evidence pertaining to the role of conditioning
intensity on outcomes after allo-HCT for CML that may guide
practice patterns. To date, no prospective or large observational
study has evaluated outcomes after MAC and RIC allo-HCT for
CML. We conducted a registry analysis from the observational
database of the Center for International Blood and Marrow Trans-
plant Research (CIBMTR) comparing outcomes after RIC and MAC
for allo-HCT in the era of TKIs. We hypothesized that RIC allo-HCT
is as efficacious as MAC allo-HCT in CML patients for survival
outcomes, considering the evidence for the graft-versus-leukemia
effect of allo-HCT.22
Patients and methods
Data sources
The CIBMTR is a combined research program of the Medical
College of Wisconsin and the National Marrow Donor Program,
which consists of a voluntary network of more than 450 trans-
plantation centers worldwide that contribute detailed data on
consecutive allogeneic and autologous transplantations to a
centralized statistical center. Observational studies conducted
by the CIBMTR are performed in compliance with all applicable
federal regulations pertaining to the protection of human research
participants. Protected health information issued in the performance
of such research is collected and maintained in the CIBMTR’s
capacity as a Public Health Authority under the Health Insurance
Portability and Accountability Act Privacy Rule.
Patients
Patients with CML between 18 and 60 years of age who underwent
allo-HCT using a sibling or unrelated donor23 between 2007 and
2014 were included in the study. Donors were matched to the
recipients at the allele level at HLA-A, HLA-B, HLA-C, and HLA-
DRB1 loci or mismatched at a single HLA locus. An upper age limit
of 60 years was introduced as an inclusion criterion to restrict the
patient population to a cohort where by age criteria both MAC and
RIC would be feasible. Patients in the chronic phase (CP) or AP24
were included. Those in BP at allo-HCT were excluded to reduce
bias, because inferior survival outcomes would be expected with
an RIC (vs MAC) regimen in BP patients, as suggested by the
results of the prospective CTN 0901 study.13 Patients with
haploidentical or cord blood transplant were excluded not only to
limit the heterogeneity of the study population but also because
of the small number of patients. Conditioning intensity was
determined per Consensus CIBMTR criteria: MAC regimens
were defined by total body irradiation (TBI) $5 Gy single dose
or $8 Gy fractionated or busulfan (Bu) dose .8 mg/kg oral or
.6.4 mg/kg IV, whereas RIC regimens were defined by Bu dose
#8 mg/kg oral or IV equivalent, melphalan (Mel) #150 mg/m2 or
TBI #2 Gy.25
Study end points
The primary end point of the study was OS. OS was defined as the
time from transplantation to death from any cause or last follow-up.
Death from any cause was considered an event. Surviving patients
were censored at last follow-up. Secondary end points included
LFS, NRM, and cumulative incidence of relapse and chronic graft-
versus-host disease (cGVHD). LFS was defined as time from
transplantation to either relapse or death from any cause, and
alive patients were censored at the time of relapse or last follow-
up. NRM was defined as death from any cause in continuous
remission and was summarized by cumulative incidence estimate
with relapse as competing risk. Relapse was summarized by
cumulative incidence estimate with NRM as the competing risk.
For relapse and NRM, patients in continuous complete remission
were censored at last follow-up. cGVHD was graded per Consensus
criteria.26 For cGVHD, death without the event was considered a
competing event.
Statistical analysis
This is a retrospective comparative cohort study comparing
outcomes after RIC vs MAC allo-HCT using related and unrelated
donors for patients with CML in CP or AP. Eligible patients were
stratified according to RIC vs MAC. The objective of this analysis
was to compare these 2 types of conditioning regimens and their
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effect on outcomes after allo-HCT. The outcomes studied were OS,
LFS, relapse rate, and incidence of cGVHD and NRM. Probabilities
of NRM, relapse, and cGVHD were calculated by cumulative
incidence function accounting for competing risks. Comparisons of
cumulative incidence across time cohorts were performed via
Gray’s test. Multivariable analyses were performed to evaluate
associations among patient-related (age, Karnofsky Performance
Score [KPS], HCT-CI, and Sorror comorbidity index27), disease-
related (time from diagnosis to transplant and disease status at
transplant), donor-related (donor type, cytomegalovirus [CMV]
match, and sex match) and transplantation-related (year of
transplant, GVHD prophylaxis, graft source, and in vivo T-cell
depletion) variables and outcomes of interest (OS, LFS, NRM,
GVHD, and relapse) using a Cox proportional hazards regres-
sion model. Forward stepwise selection was used to identify
significant covariates that influenced outcomes. Disease status at
transplant was categorized into chronic phase 1 (CP1), CP2
and beyond (CP21), and AP. Covariates with P , .05 were
considered significant. The proportional hazards assumption for
Cox regression was tested by adding a time-dependent covariate
for each risk factor and each outcome. Covariates violating the
proportional hazards assumption were added as time-dependent
covariates in the Cox regression model. Adjusted probabili-
ties for OS, LFS, NRM, cGVHD, and relapse were calculated
based on the final Cox models.28,29 The findings of multivariate
analysis of cGVHD, NRM, and relapse by the Cox regression
model were confirmed using the Fine-Gray model of competing
risks. Interactions between the main effect (conditioning regimen)
and significant covariates were examined. Power analysis was
conducted; it was assumed that OS at 5 years for RIC was
60%. The median censoring time was assumed to be 7 years.
Assuming OS of 45% at 5 years for MAC (relative risk, 1.56), the
study had 92% statistical power. All analyses were performed
using SAS 9.4.
Results
Patient, disease, and transplantation characteristics
Using the eligibility criteria, a total of 1395 patients were included in
the study population, of which 1204 received MAC and 191
received RIC. Patient, disease, and transplantation characteristics
were similar, with a few exceptions (Table 1). The median ages
in MAC and RIC groups were 43 (range, 18-60) and 51 (range,
19-60) years, respectively. There were more males in the MAC
group (60%) than the RIC group (47%). A greater proportion of
MAC patients (70%) had KPS$90 compared with RIC (58%), and
20% and 30% of MAC and RIC recipients, respectively, had
HCT-CI$3. As might be expected, the RIC cohort was enriched for
older patients with lower KPS and higher HCT-CI. Median time from
diagnosis to transplant was 23 months in the MAC cohort and
27 months in the RIC cohort. In both the cohorts, three-fourths of
the patients received a peripheral blood graft. CP1 was the most
common status prior to allo-HCT in both the MAC (42%) and
RIC (48%) cohorts (P 5 .34). TKI was used for treatment before
allo-HCT in 93% of MAC patients and 94% of RIC patients.
In the MAC cohort, Bu/Cy was the most common regimen
employed (40%), followed by Flu/Bu4 (24%) and Cy/TBI (24%).
In the RIC cohort, Flu/Bu2 was the most common regimen (51%)
followed by Flu/Mel (27%). In vivo T-cell depletion using ATG or
alemtuzumab was used less commonly in the MAC cohort (22%)
than the RIC cohort (47%). The majority of patients in both
cohorts (88% in MAC and 90% in RIC) were from the North
America or South America. Approximately 5% of patients were
from Europe. Eastern Mediterranean, Southeastern Asian, and
Western Pacific countries made up ;5% of both cohorts. The
median follow-up of survivors was 52 and 60 months in the MAC
and RIC cohorts, respectively.
Of the 596 patients categorized as CP1 at the time of allo-HCT
(504 in MAC and 92 in RIC cohort) (Table 1), the indication for allo-
HCT in 78% (n 5 467) was failure to achieve deeper (cytogenetic
and/or molecular) remission with nontransplant therapies. The
indication was not available for the other 22% and is presumed to
be intolerance to TKIs. A total of 465 patients were in AP at the time
of allo-HCT (405 in MAC [34%] and 60 in RIC [31%]) (Table 1).
A total of 230 patients (57%) in the MAC cohort and 31 patients
(52%) in the RIC cohort had presented with AP or BP and achieved
at least a hematologic response prior to allo-HCT. The baseline
cytogenetic information (pre-HCT) was not available in the 2
cohorts given the type of data forms used for this study (Transplant
Essential Data).
OS
On multivariable analysis, no significant difference in OS was
seen between the MAC and RIC cohorts (HR, 0.99, P 5 .95)
(Table 2; Figure 1D). The adjusted probabilities of 5-year OS
were 53% (95% confidence interval [CI], 50%-56%) and 53%
(95% CI, 45%-60%) for the MAC and RIC cohorts, respectively
(P 5 .98) (Table 3). Variables associated with higher mortality
included unrelated donor (matched or partially matched), CMV
(donor seronegative/recipient seropositive and both donor and
recipient seropositive), peripheral blood graft, and KPS ,90%
(Table 2). Additionally, compared with those in CP1, patients in
AP (HR, 1.59; P5 .0006) and CP21 (HR, 1.18; P 5 .0008) had
an increased risk of mortality after allo-HCT.
LFS
On multivariable analysis, no significant difference was observed
when comparing the MAC and RIC cohorts (HR, 1.13; P 5 .29)
(Table 2; Figure 1C). The adjusted 5-year LFS rates for MAC and
RIC were 44% (95% CI, 41%-47%) and 43% (95% CI 36%-
51%), respectively (P 5 .81; Table 3). Variables associated with
higher risk of treatment failure (inverse of LFS) included disease
states of AP (HR, 1.47; P , .0001) and CP21 (HR, 1.43; P 5
.0002) at allo-HCT (compared with CP1) and KPS ,90% (HR,
1.49; P , .0001).
NRM and relapse
On multivariable analysis, there was no significant difference in
NRM between the MAC and RIC groups (Cox regression model:
HR, 1.01; P5 .97; Fine-Gray model: HR, 0.92; P5 .57) (Table 2;
Figure 1A; supplemental Table 2). The adjusted 5-year NRM rates
were 32% (95% CI, 29%-35%) and 29% (95% CI, 22%-36%)
in the MAC and RIC cohorts, respectively (P 5 .53; Table 3).
Independent of the conditioning intensity, recipient age (40-49
years: HR, 1.47; P 5 .02; 50-59 years: HR, 1.66; P 5 .003
[compared with 18-29 years age group]), donor type (matched
unrelated and partially matched unrelated compared with
matched sibling), CMV (donor and recipient seropositivity), and
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Table 1. Characteristics of patients aged 18 to 60 years undergoing allo-HCT using MAC vs RIC for CML, 2007-2014
Variable MAC (n 5 1204) RIC (n 5 191) P
Follow-up of survivors, median (range), mo 52 (4-102) 60 (7-101)
Number of centers 163 76
Patient related
Age at transplant, median (range), y 43 (18-60) 51 (19-60) ,.001
Age at transplant, y ,.001
18-29 212 (18) 17 (9)
30-39 276 (23) 21 (11)
40-49 404 (34) 47 (25)
50-59 312 (26) 106 (55)
Sex ,.001
Male 722 (60) 90 (47)
Female 482 (40) 101 (53)
KPS, % ,.001
90-100 845 (70) 110 (58)
,90 267 (22) 72 (38)
Missing 92 (8) 9 (5)
WHO region .60
Africa 1 (,1) 0
Americas 1054 (88) 172 (90)
Eastern Mediterranean 22 (2) 0
Europe 78 (6) 10 (5)
Southeastern Asian 21 (2) 4 (2)
Western Pacific 27 (2) 5 (3)
Missing 1 (,1) 0
Sorror comorbidity index (HCT-CI) .003
0 525 (44) 64 (34)
1 132 (11) 27 (14)
2 125 (10) 25 (13)
31 246 (20) 58 (30)
Missing 176 (15) 17 (9)
Disease related
Disease status prior to transplant .20
CP1 504 (42) 92 (48)
AP 405 (34) 60 (31)
CP21 278 (23) 38 (20)
CP, NOS 17 (1) 1 (,1)
Prior treatment .85
No 9 (,1) 1 (,1)
Yes 1185 (98) 189 (99)
Missing 10 (,1) 1 (,1)
Use of TKI prior to HCT .89
No 73 (6) 11 (6)
Yes 1121 (93) 179 (94)
Missing 10 (,1) 1 (,1)
TKI used pre-HCT .11
No TKI used 73 (6) 11 (6)
Data are presented as n (%) of patients unless otherwise indicated.
ATG, anti-thymocyte globulin; BM, bone marrow; CP, chronic phase; CSA, cyclosporine; Cy; cyclophosphamide; F, female; Flu, fludarabine; M, male; NOS, not otherwise specified; PB,
peripheral blood; TAC, tacrolimus; URD; unrelated donor; WHO, World Health Organization.
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Table 1. (continued)
Variable MAC (n 5 1204) RIC (n 5 191) P
Imatinib 1 dasatinib 1 nilotinib 250 (21) 52 (27)
Imatinib 1 dasatinib 295 (25) 55 (29)
Imatinib 1 nilotinib 73 (6) 13 (7)
Dasatinib 1 nilotinib 35 (3) 8 (4)
Imatinib 395 (33) 43 (23)
Dasatinib 52 (4) 7 (4)
Nilotinib 21 (2) 1 (,1)
Missing 10 (,1) 1 (,1)
Time to HCT from diagnosis, mo 23 (,1-608) 27 (4-281) .03
Time to HCT from diagnosis, mo .12
0-12 316 (26) 41 (21)
12-36 496 (41) 75 (39)
$36 391 (32) 74 (39)
Missing 1 (,1) 1 (,1)
Donor-related
Donor type .29
HLA-identical sibling 539 (45) 73 (38)
Well-matched unrelated 447 (37) 85 (45)
Partially matched unrelated 125 (10) 21 (11)
Mismatched unrelated 9 (,1) 2 (1)
Unrelated (matching indeterminable) 84 (7) 10 (5)
URD-recipient HLA-matching .10
3 0 1 (,1)
5 1 (,1) 0
6 5 (,1) 0
7 101 (15) 19 (16)
8 407 (61) 79 (67)
Missing 151 (23) 19 (16)
Donor-recipient sex match .003
M-M 456 (38) 63 (33)
M-F 271 (23) 66 (35)
F-M 264 (22) 27 (14)
F-F 209 (17) 34 (18)
Missing 4 (,1) 1 (,1)
Donor-recipient CMV status .36
1/1 377 (31) 67 (35)
1/2 99 (8) 18 (9)
2/1 272 (23) 47 (25)
2/2 287 (24) 41 (21)
URD age, median (range), y 30 (18-61) 29 (20-59) .22
URD age, y .15
18-29 271 (41) 59 (50)
30-39 137 (21) 27 (23)
40-49 103 (15) 17 (14)
50-59 37 (6) 2 (2)
Data are presented as n (%) of patients unless otherwise indicated.
ATG, anti-thymocyte globulin; BM, bone marrow; CP, chronic phase; CSA, cyclosporine; Cy; cyclophosphamide; F, female; Flu, fludarabine; M, male; NOS, not otherwise specified; PB,
peripheral blood; TAC, tacrolimus; URD; unrelated donor; WHO, World Health Organization.
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peripheral blood graft were associated with a significantly higher
risk of NRM.
Multivariable analysis confirmed that the risk of relapse between the
2 cohorts was time dependent; RIC had a significantly increased
risk of relapse early after allo-HCT (in the first 5 months) (HR, 1.85;
P 5 .001), but no statistically significant difference was observed
during the late (.5 months) allo-HCT course (Table 2; Figure 1B).
Similar results were obtained with the Fine-Gray model (#5
months: HR, 1.86; P 5 .001; .5 months: HR, 0.60; P 5 .06;
supplemental Table 2). The adjusted cumulative incidence rates
of relapse at 5 years were 26% (95% CI, 23%-28%) and 25%
(95% CI, 19%-31%) for MAC and RIC, respectively (P 5 .96;
Table 3). In addition to the conditioning intensity, disease status,
KPS, and donor type affected the relapse risk. AP (HR 1.87,
P , .0001) and CP21 (HR, 1.79; P , .0001) carried an
increased risk of relapse relative to CP1. Well-matched and
partially matched unrelated donors and KPS $90% were
associated with a lower relapse risk. An evaluation of the causes
of death in the 2 cohorts (supplemental Table 1) did not reveal any
significant differences between the cohorts; disease relapse
(;30% in both) and GVHD (29% in both) were the dominant
causes of death in both cohorts.
cGVHD
Multivariable analysis showed a significantly reduced risk of cGVHD
(Cox model: HR, 0.77; 95% CI, 0.61-0.97; P 5 .02; Fine-Gray
model: HR, 0.78; P 5 .03) with RIC relative to MAC (Table 2;
supplemental Table 2). The adjusted cumulative incidence rates of
cGVHD at 1 and 5 years were 50% (95% CI, 47%-53%) and 59%
(95% CI, 56%-62%) after MAC compared with 41% (95% CI,
33%-48%) and 51% (95% CI, 44%-59%) with RIC (P 5 .02 and
.07, respectively) (Table 3). In patients without in vivo T-cell
depletion, the incidence of cGVHD was not significantly different
relative to those receiving ATG (HR, 1.13; P 5 .18) but was
significantly higher compared with those receiving alemtuzumab
(HR, 2.76; P 5 .002). Compared with ATG, alemtuzumab
Table 1. (continued)
Variable MAC (n 5 1204) RIC (n 5 191) P
$60 2 (,1) 0
Missing 115 (17) 13 (11)
Transplant related
Year of transplant .08
2007-2008 261 (22) 30 (16)
2009-2010 311 (26) 60 (31)
2011-2012 302 (25) 56 (29)
2013-2014 330 (27) 45 (24)
Graft type .58
BM 293 (24) 43 (23)
PB 911 (76) 148 (77)
Conditioning regimen
TBI 6 Cy 6 others (376; 31%) Bu2 1 Flu 6 others (97; 51%)
Bu 1 Cy 6 others (492; 41%) Flu 1 Mel 6 other (53; 28%)
Bu4 1 Flu 6 others (302; 25%) Cy 6 Flu 6 TBI 6 others (18; 9%)
Others (34; 3%) TBI 6 Flu 6 others (11; 6%)
Others (12; 6%)
ATG/alemtuzumab ,.001
ATG alone 258 (21) 72 (38)
Alemtuzumab alone 15 (1) 18 (9)
No ATG or alemtuzumab 929 (77) 101 (53)
Missing 2 (,1) 0
GVHD prophylaxis .26
Ex vivo T-cell depletion/CD34 selection 20 (2) 1 (,1)
TAC based 712 (59) 124 (65)
CSA based 414 (34) 55 (29)
Other 53 (4) 11 (6)
Missing 5 (,1) 0
Data are presented as n (%) of patients unless otherwise indicated.
ATG, anti-thymocyte globulin; BM, bone marrow; CP, chronic phase; CSA, cyclosporine; Cy; cyclophosphamide; F, female; Flu, fludarabine; M, male; NOS, not otherwise specified; PB,
peripheral blood; TAC, tacrolimus; URD; unrelated donor; WHO, World Health Organization.
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Table 2. Multivariable analysis for patients aged 18 to 60 years undergoing allo-HCT using MAC vs RIC for CML, 2007-2014
No. of patients (evaluable) HR 95% CI P
OS
MAC 1204 1.0
RIC 191 0.99 0.79-1.25 .95
Disease status .002
CP1 596 1.0
AP 465 1.59 1.13-2.24 .0006
CP21 316 1.18 0.85-1.63 .0008
CP, NOS 11 1.96 0.71-5.36 .28
Missing 7 0.87 0.63-1.20 .17
KPS .0003
$90% 955 1.0
,90% 339 1.41 1.18-1.69 .0002
Missing 101 1.08 0.76-1.54 .66
Graft type .004
BM 336 1.0
PB 1059 1.36 1.10-1.66 .004
Donor type .02
HLA-identical sibling 612 1.0
Well-matched unrelated 532 1.32 1.09-1.60 .004
Partially matched unrelated 146 1.45 1.10-1.89 .007
Mismatched unrelated 11 1.65 0.73-3.74 .23
URD matching TBD 94 1.29 0.09-1.83 .15
CMV match .03
1/1 444 1.0
1/2 117 0.93 0.68-1.26 .63
2/1 319 1.11 0.90-1.37 .33
2/2 328 0.76 0.60-0.95 .02
Missing 187 1.04 0.76-1.42 .79
LFS
MAC 1190 1.0
RIC 191 1.13 0.92-1.39 .29
Disease status ,.0001
CP1 593 1.0
AP 459 1.47 1.23-1.74 ,.0001
CP21 311 1.43 1.19-1.73 .0002
CP, NOS 11 1.74 0.86-3.53 .12
Missing 7 1.44 0.53-3.86 .47
KPS ,.0001
$90% 948 1.0
,90% 337 1.49 1.26-1.75 ,.0001
Missing 96 0.98 0.73-1.32 .90
Relapse £5 mo
MAC 1183 1.0
RIC 191 1.85 1.27-2.70 .001
Relapse >5 mo
MAC 922 1.0
RIC 137 0.64 0.37-1.08 .097
TBD, to be determined.
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Table 2. (continued)
No. of patients (evaluable) HR 95% CI P
Disease status ,.0001
CP1 593 1.0
AP 459 1.87 1.44-2.41 ,.0001
CP21 311 1.79 1.34-2.39 ,.0001
CP, NOS 11 1.58 0.50-5.02 .43
KPS ,.0001
$90% 944 1.0
,90% 334 1.81 1.42-2.29 ,.0001
Missing 96 1.06 0.69-1.62 .80
Donor type .005
HLA-identical sibling 604 1.0
Well-matched unrelated 528 0.64 0.50-0.82 .0004
Partially matched unrelated 143 0.64 0.43-0.95 .03
Mismatched unrelated 10 0.82 0.20-3.33 .78
URD matching TBD 89 0.75 0.45-1.23 .25
NRM
MAC 1190 1.0
RIC 191 1.01 0.76-1.34 .97
Age, y .02
18-29 226 1.0
30-39 295 1.27 0.88-1.82 .20
40-49 445 1.47 1.05-2.05 .02
50-59 415 1.66 1.18-2.33 .003
Graft type .02
BM 333 1.0
PB 1048 1.34 1.04-1.72 .02
Donor type .0002
HLA-identical sibling 608 1.0
Well-matched unrelated 531 1.56 1.23-1.99 .0003
Partially matched unrelated 143 1.89 1.28-2.53 .0001
Mismatched unrelated 10 2.73 0.81-5.99 .03
URD matching TBD 89 1.46 1.08-2.29 .09
CMV match .02
1/1 440 1.0
1/2 117 1.01 0.69-1.48 .95
2/1 316 1.22 0.94-1.58 .13
2/2 326 0.74 0.55-0.97 .04
Missing 182 0.97 0.67-1.39 .85
cGVHD
MAC 1177 1.0
RIC 187 0.77 0.61-0.97 .02
Graft type ,.0001
BM 327 1.0
PB 1037 1.75 1.46-2.10 ,.0001
GVHD prophylaxis .0005
TAC 821 1.0
T-cell depletion/CD34 19 0.26 0.11-0.58 .001
TBD, to be determined.
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significantly decreased the risk of cGVHD (HR, 0.41; P 5 .007).
In addition, female donor/male recipient had a 30% higher cGVHD
risk than male donor and recipient (P 5 .006).
Subgroup analysis
CP21 and AP. Multivariable analysis of a prespecified
subgroup of CP21 and AP at the time of allo-HCT was done
to see if there were differences in outcomes in this group of
patients with higher-risk disease (Table 4). The analysis showed
that in the RIC cohort, OS (HR, 1.18; P 5 .26) and LFS (HR,
1.27; P 5 .08) were not significantly different when compared
with MAC. NRM was also not affected by the conditioning
intensity in this high-risk subgroup (HR, 1.32; P 5 .17). The risk
of relapse, however, varied by the time from allo-HCT: RIC
patients with CP21/AP carried a higher risk of early relapse (HR,
2.06; P 5 .002) but had a relapse risk similar to MAC later
(.5 months) in the course (HR, 0.46; P 5 .06). The cumulative
incidence of cGVHD did not differ significantly between MAC
and RIC (HR, 0.83; P 5 .26).
Discussion
Although allogeneic transplantation is no longer a first-line
treatment of CML in CP1 in the United States, many patients who
are resistant to or intolerant of TKIs continue to require it.2,30 The
European Leukemia Network, in addition, recommends allo-HCT for
all patients with AP or BP at diagnosis.2 Since the approval of
the TKI imatinib mesylate in 2001 based on the phase 3 IRIS
study,31,32 the great majority of CML patients undergo allo-HCT
later in their course. Nonetheless, the question about the optimal
allogeneic transplant conditioning regimen intensity for CML is
relevant and has been addressed for the first time in this
observational study. Our data illustrate that in the era of TKIs,
RIC is an appropriate alternative to MAC for CML patients given
the equivalent survival.
Studies have shown that RIC allo-HCT for CML patients can
prolong survival with acceptable NRM. A retrospective study by
Crawley et al reported the outcomes after RIC allo-HCT and
demonstrated its feasibility in 186 CML patients.11 The median
age of patients was 50 years; 64% patients were in CP1, 13% in
CP2, 17% in AP, and 6% in BP. OS and progression-free survival
at 3 years were 58% and 37%, respectively. Warlick et al
described outcomes in 306 CML patients of age $40 years
undergoing RIC allo-HCT and reported to CIBMTR.12 Of these,
38% patients were aged 40 to 49 years, 39% were 50 to
59 years, and 23% were $60 years. The 3-year OS (54%, 52%,
and 41%) and 1-year NRM (18%, 20%, and 13%) were similar
across age groups. LFS and relapse were similar across age
groups in CP1 patients.
Our study makes several important observations. Patients with AP
and CP21 at allo-HCT had higher mortality compared with those
in CP1, which could be explained by the advanced disease
outstripping the ensuing graft-versus-leukemia effect early in the
course. In addition, LFS did not differ significantly between the
2 conditioning intensities. The analysis also failed to show any
difference in NRM between the 2 cohorts. RIC was associated
with 85% greater risk of early after allo-HCT relapse but did not
have a statistically significant difference beyond 5 months after
allo-HCT. The higher early relapse risk with RIC allo-HCT could be
explained by the modest cytoreduction engendered by the
conditioning, enabling early relapse. However, the increased
early relapse risk in the RIC cohort did not translate into worse
OS due to potentially successful salvage treatment with TKIs
and/or donor lymphocyte infusion (DLI) in those relapsing.
Furthermore, in multivariable analysis, adjusting for many fac-
tors, including in vivo T-cell depletion, the cumulative inci-
dence of cGVHD was notably lower in the RIC cohort than
the MAC cohort in the first year after allo-HCT but lost
statistical significance by 3 years. We can speculate that the
use of nonmyeloablative (18%) and reduced-intensity condition-
ing (82%) may be associated with lower incidence of cGVHD,
through potentially less tissue injury and cytokine release
compared with MAC, as was also reported in BMT CTN 0901
study,13 although the strength of evidence in support of this
argument would be considered weak based on other published
studies.33-37 It is also possible that a higher frequency of TKI
use after RIC allo-HCT for treatment or prevention of CML
relapse may have curbed the cGVHD risk.38-40 In multivariable
analysis, no significant interaction was found between condi-
tioning intensity and disease status at the time of allo-HCT. The
Table 2. (continued)
No. of patients (evaluable) HR 95% CI P
CSA 457 0.82 0.70-0.96 .01
Other 64 0.67 0.46-0.99 .04
ATG/alemtuzumab .004
ATG alone 319 1.0
Alemtuzumab alone 33 0.41 0.21-0.78 .007
No ATG/alemtuzumab 1012 1.13 0.94-1.36 .18
Sex match .007
M-M 508 1.0
M-F 331 0.91 0.75-1.10 .33
F-M 284 1.30 1.08-1.58 .006
F-F 241 1.06 0.87-1.30 .57
TBD, to be determined.
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survival outcomes in patients who were in AP or CP21 at allo-
HCT were not significantly different between the conditioning
cohorts. Furthermore, no significant interaction was detected
between conditioning intensity and other covariates such as
age, KPS, HCT-CI, donor type, donor–recipient CMV status,
graft source, in vivo T-cell depletion, year of HCT, and time from
diagnosis to HCT; this has been demonstrated in a forest plot
(Figure 2).
This observational study has limitations. The major limitation of this
analysis is that the information on CML therapies (including TKIs
and DLI) used after HCT was not available. The use of TKIs as
maintenance therapy or for treatment of relapse/progression of
CML and of DLI preemptively or for salvage, thereby preventing
relapse and/or improving OS in relapsed CML patients in the RIC
cohort, is certainly within the realm of possibility. Having 5 Food
and Drug Administration–approved TKIs in the United States
by 2012 suggests that the great majority of study patients had
a decent probability of access to effective TKIs after HCT,
and not having that data is a serious limitation. Nonetheless, the
study aimed at evaluating the impact of conditioning intensity on
allo-HCT outcomes and did not intend to examine the role of
prophylactic or maintenance after allo-HCT TKIs. Even though
centers have been employing maintenance TKIs,41-44 a recent
CIBMTR study demonstrated no significant impact of mainte-
nance TKI therapy on risk of cGVHD, NRM, relapse, LFS, and OS
following allo-HCT in CML patients.45 Patients who underwent
MAC and RIC alloHCT between 2007 and 2014, and received TKI
pre-HCT were included in that study. A landmark analysis was
performed at day 100 after HCT. A total of 390 patients were
included in the analysis (TKI maintenance, n5 89; no TKI maintenance,
n 5 301). A major proportion of both cohorts underwent MAC allo-
HCT (85% in TKI cohort and 83% in no TKI cohort). With so few
RIC patients, the study findings cannot be interpreted as lack of
evidence in favor of maintenance TKIs after RIC allo-HCT as a
relapse risk-reduction strategy.
An additional caveat of the study is that information on the depth
of response prior to allo-HCT (ie, cytogenetic and/or molecular
response to therapy) was not available. Having this useful data
may further enable demonstration of the impact of the depth of
response on outcomes and interaction with conditioning intensity
and therefore, may theoretically play a role in the conditioning
selection process. In addition, a potential demerit of the study is
that the conditioning intensity (MAC vs RIC) selection criteria
were not known; we can speculate that the treating physician
made the decision to use a specific conditioning regimen based
on certain clinical variables, the prevalent institutional guidelines,
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Figure 1. Outcomes after MAC versus RIC alloHCT for CML. (A) Adjusted curves for NRM after allo-HCT for CML using MAC vs RIC. (B) Adjusted curves for disease relapse after
allo-HCT for CML using MAC vs RIC. (C) Adjusted curves for LFS after allo-HCT for CML using MAC vs RIC. (D) Adjusted curves for OS after allo-HCT for CML using MAC vs RIC.
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and the available clinical trials. The only way to prevent the
selection bias would be to conduct a prospective randomized
study. We tried to adjust for confounding caused by the different
variables by taking them into account in the multivariable analysis,
but the possibility of residual confounding remains. Finally, we
analyzed the data in patients who underwent the allo-HCT but
could not ascertain the justification for it in all patients. We can
safely assume that the decision to proceed to allo-HCT was
appropriate in those who were diagnosed with CML in AP or BP,
but the reason for allo-HCT in others is not apparent in the data
forms.
In summary, the current study represents the comparison of CML
patients undergoing MAC and RIC allo-HCT in the era of TKIs and
supports the notion that RIC allo-HCT is an appropriate alternative
to MAC for CML. However, the lack of difference in OS between
the MAC and RIC allo-HCT in the analysis is not to be construed as
an argument in favor of selecting RIC over MAC for CML patients.
On the contrary, the analysis revealed that compared with MAC,
RIC allo-HCT afforded similar survival, albeit at the expense of
increased early post–allo-HCT relapse risk. It is paramount to
recognize that the intent of the study was not to identify a superior
conditioning intensity between MAC and RIC but to demonstrate
that OS and LFS in CML patients who are unable to proceed
to MAC allo-HCT on clinical grounds are similar, should they
receive RIC allo-HCT. Examining the interactions between condi-
tioning intensity and several clinical variables did not suggest
any advantage for RIC over MAC or vice versa to help make a
recommendation on selection of conditioning intensity in CML
patient subgroups based on these clinical variables. To conclude,
this study is significant in light of the fact that a confirmation of the
findings through a prospective randomized controlled trial is not
likely to be attempted in the current times, where patients have
Table 4.Multivariable analysis for patients aged 18 to 60 years in AP/
CP21 undergoing allo-HCT using MAC vs RIC for CML, 2007-2014
n HR 95% CI P
cGVHD
MAC 668 1
RIC 97 0.83 0.60-1.15 .26
Relapse £5 mo
MAC 672 1
RIC 98 2.06 1.31-3.23 .002
Relapse >5 mo
MAC 503 1
RIC 99 0.46 0.20-1.05 .06
NRM
MAC 672 1
RIC 98 1.32 0.89-1.94 .17
LFS
MAC 672 1
RIC 98 1.27 0.97-1.66 .08
OS
MAC 683 1
RIC 98 1.18 0.88-1.57 .26
Table 3. Adjusted probabilities of outcomes in CML patients aged 18 to 60 years undergoing allo-HCT using MAC vs RIC, 2007-2014
MAC (n 5 1204) RIC (n 5 191)
Outcomes
No. of patients
(evaluable) Probability (95% CI), %
No. of patients
(evaluable) Probability (95% CI), % P
OS, y 1204 191
1 831 71 (68-73) 133 72 (66-78) .61
3 501 58 (55-60) 86 58 (51-65) .91
5 272 53 (50-56) 49 53 (45-60) .98
LFS, y 1190 191
1 731 63 (60-66) 106 58 (51-65) .15
3 423 50 (47-53) 70 46 (39-53) .31
5 222 44 (41-47) 40 43 (36-51) .81
Relapse, y 1190 191
1 731 16 (14-18) 106 21 (16-27) .10
3 423 23 (21-26) 70 25 (19-31) .49
5 222 26 (23-28) 40 25 (19-31) .96
NRM, y 1190 191
1 731 21 (18-23) 106 19 (14-24) .50
3 423 28 (25-30) 70 26 (20-33) .71
5 222 32 (29-35) 40 29 (22-36) .53
cGVHD, y 1182 188
1 316 50 (47-53) 64 41 (33-48) .02
3 122 58 (55-61) 27 51 (43-58) .08
5 57 59 (56-62) 16 51 (44-59) .07
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access to an increasing number of potent TKIs and there is a
possibility of long-term remission with treatment-free intervals and,
consequently, fewer patients in need of allo-HCT.
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